Sean McClain, AbSci

On a mis­sion to 'u­ni­fy' drug dis­cov­ery and cell-line de­vel­op­ment, Ab­Sci ac­quires AI out­fit De­n­ovi­um

Imag­ine dis­cov­er­ing a drug and cell line at the click of a but­ton. That’s the goal of Ab­Sci CEO Sean Mc­Clain — and on Mon­day, he …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.